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Metabolomic and Genome-wide Association
Studies Reveal Potential Endogenous
Biomarkers for OATP1B1
SW Yee1, MM Giacomini1, C-H Hsueh1, D Weitz2, X Liang1, S Goswami1, JM Kinchen3, A Coelho1,
AA Zur1, K Mertsch2, W Brian4, DL Kroetz1 and KM Giacomini1,5
Transporter-mediated drug-drug interactions (DDIs) are a major cause of drug toxicities. Using published genome-wide association studies
(GWAS) of the human metabolome, we identified 20 metabolites associated with genetic variants in organic anion transporter, OATP1B1
(P < 53 1028). Of these, 12 metabolites were significantly higher in plasma samples from volunteers dosed with the OATP1B1 inhibitor,
cyclosporine (CSA) vs. placebo (q-value < 0.2). Conjugated bile acids and fatty acid dicarboxylates were among the metabolites discovered
using both GWAS and CSA administration. In vitro studies confirmed tetradecanedioate (TDA) and hexadecanedioate (HDA) were novel
substrates of OATP1B1 as well as OAT1 and OAT3. This study highlights the use of multiple datasets for the discovery of endogenous
metabolites that represent potential in vivo biomarkers for transporter-mediated DDIs. Future studies are needed to determine whether these
metabolites can serve as qualified biomarkers for organic anion transporters. Quantitative relationships between metabolite levels and
modulation of transporters should be established.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 Currently, regulatory agencies recommend the use of in vitro
studies coupled with particular criteria to predict transporter-
mediated clinical DDIs, and to trigger the conduct of expensive
clinical DDI studies. Use of these assays and criteria results in
many false-positive results.49,50 Thus, endogenous biomarkers for
membrane transporters are needed to better predict transporter-
mediated clinical DDIs.
WHAT QUESTION DID THIS STUDY ADDRESS?
 Can novel biomarkers for transporters be identiﬁed through
multiscale approaches, including analysis of published genome-
wide association studies of endogenous metabolites, metabolomic
proﬁling of samples from clinical DDI studies, and uptake studies
in transporter expressing cell lines?
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 Using multiscale approaches, we identiﬁed potential bio-
markers of OATP1B1, which, if validated, may be used as
probes for clinical DDIs. This is the ﬁrst study showing that
OATP1B1 interacts with fatty acid dicarboxylates.
HOW THIS MIGHT CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE
 Endogenous biomarkers, such as those identiﬁed in this
study, can be used during drug development to better predict
clinical DDIs.
Inhibition or induction of transporters in the liver, kidney, and
intestine can result in clinical drug-drug interactions (DDIs). To
predict whether a DDI is likely to occur and whether a speciﬁc
clinical study is warranted, the US Food and Drug Administra-
tion, the European Medical Agency, and Japan’s Pharmaceuticals
and Medical Devices Agency have issued guidances that include a
set of criteria based on cellular assays of drug transporter interac-
tions.1–3 Although, in general, in vitro cellular assays are good
predictors of clinical DDIs, they are fairly conservative, erring on
the side of excess false-positive over false-negative results.
Endogenous metabolites that are selective substrates for one or a
few drug transporters could be used during early clinical trials as
biomarkers for potential clinical DDIs. These biomarkers could
supplement in vitro studies and may reduce false-positive results
from in vitro studies, as well as the cost and time required for
clinical development.
For example, creatinine is a substrate of several organic cation
and anion transporters in the kidneys, including organic cation
transporter 2 (SLC22A2), multidrug and toxin extrusion protein
1 (SLC47A1), and organic anion transporter 2 (OAT2;
SLC22A7).4,5 A pharmaceutical agent that inhibits one or more
of these transporters may cause an increase in serum creatinine
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levels.4,6 Thus, although not ideal because it is also a biomarker
of kidney dysfunction, creatinine was suggested as a biomarker
for renal transporter-mediated DDIs. Several metabolites that are
more promising have been discovered in studies of transporter
knockout mice and/or clinical studies of selected transporter-
mediated DDIs. Examples include 6b-hydroxycortisol, N-methylni-
cotinamide, and bilirubin glucuronide, which are proposed as
potential biomarkers of OAT3, multidrug and toxin extrusion pro-
tein 1/multidrug and toxin extrusion protein 2, and OATP1B1/
OATP1B3/MRP2, respectively.7–9 To date, there has been no sys-
tematic study to identify endogenous biomarkers of transporter-
mediated DDIs.
The goal of this study was to identify endogenous metabolites
for OATP1B1, which could serve as biomarkers of potential
OATP1B1-mediated DDIs. Such metabolites could also provide
valuable information about the biological function of the trans-
porter. OATP1B1, a liver OAT, has been recognized by the
International Transporter Consortium, the US Food and Drug
Administration, and the European Medical Agency as an
important protein in mediating DDIs.10 Using data available
from genome-wide association studies (GWAS) and clinical sam-
ples from a DDI study between pravastatin and cyclosporine
(CSA), we discovered 12 metabolites that were signiﬁcantly asso-
ciated with genetic variants in OATP1B1 and exhibited increased
plasma levels after administration of CSA, an inhibitor of
OATP1B1. Following this multitiered approach, several of
the 12 metabolites were found to be inhibitors or substrates
of OATP1B1 in cell lines overexpressing the transporters
(Figure 1). Collectively, our multiscale approach resulted in the
identiﬁcation of endogenous metabolites, which represent promis-
ing candidate biomarkers of DDIs mediated by OATP1B1.
RESULTS
GWAS from publicly available sources revealed novel
endogenous metabolites for SLC transporters
The metabolomics GWAS server (http://mips.helmholtz-muen-
chen.de/proj/GWAS/gwas/index.php) allows access to genome-
wide summary statistics for explorations of genetic loci
inﬂuencing 529 human metabolites in up to 7,824 adult
Figure 1 Schematic of the workflow applied to discovery and functional studies for identification of endogenous biomarkers for organic anion transport-
er, OATP1B1. This multiscale approach includes (a) using publicly available genome-wide association studies for human metabolites, (b) performing
metabolomic profiling of a cyclosporine (CSA)/pravastatin drug-drug interaction (DDI) study, and (c) conducting in vitro studies in transporters expressing
cells. SNPs within 25,000 bp up and downstream of 390 solute carrier (SLC) transporter genes were associated with 529 metabolites. In addition, plas-
ma samples from 20 healthy volunteers taken from a CSA/pravastatin randomized crossover DDI study were used to profile metabolite levels. Twelve
metabolites were significant in both datasets (see Results section). Transporter uptake and inhibition studies were performed to determine whether the
selected six metabolites were inhibitors and/or substrates of OATP1B1 and 10 other selected transporters.
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individuals from two European ancestry cohorts.11,12 Supple-
mentary Table S1 shows associations, with P values < 0.0001,
for all the metabolites signiﬁcantly associated with the single-
nucleotide polymorphisms (SNPs) in SLC transporters. From
the 390 SLC transporters extracted, 312 transporters were asso-
ciated with at least one metabolite with P values < 0.0001.
Several metabolites, which are known substrates of the SLC
transporters, showed signiﬁcant association with the SNPs
within or near transporter genes (Supplementary Table S2).
In addition, the association analyses showed many novel
metabolites that have not been previously reported to be associ-
ated with particular transporters. For example, SLC2A9, a uric
acid transporter,13 which also transports fructose,14 was strong-
ly associated with plasma histidine levels in addition to uric
acid levels. A second example is SLC5A6, a multivitamin trans-
porter,15 which was strongly associated with plasma mannose
levels. Supplementary Table S2 highlights the 41 SLC trans-
porters that have at least one metabolite associated with it at
genome-wide signiﬁcance (P < 5 3 1028).
OATP1B1 nonsynonymous variant, Val174Ala (c.521T>C,
rs4149056), was associated with higher plasma levels of
fatty acid dicarboxylic acids
The functional variant of OATP1B1, OATP1B1-Val174Ala
(rs4149056), was signiﬁcantly associated with 20 endogenous
metabolites (Supplementary Table S2, Supplementary Table
S3) in the genome-wide human metabolome study (Figure 2a).
Among them are bile acids and steroids that have been reported
previously to be substrates of OATP1B1.16 The other metabo-
lites, which showed signiﬁcantly higher levels in individuals who
were carriers of the OATP1B1-Val174Ala variant, were fatty acid
dicarboxylates and lysolipids. Examples of fatty acid dicarboxy-
lates were tetradecanedioate (TDA), hexadecanedioate (HDA),
and octadecanedioate (ODA); examples of lysolipids with altered
levels were 1-arachidonoylglycerophosphoethanolamine and 1-
arachidonoylglycerophosphoinositol (Supplementary Table S2,
Supplementary Table S3). Furthermore, the genome-wide asso-
ciation for some of these metabolites showed that OATP1B1 was
the top association locus, for example, for the sulfated and glucur-
onidated bile acids and fatty acid dicarboxylates (Figure 2a). The
levels of other known substrates of OATP1B1, such as biliru-
bin,17 were also signiﬁcantly associated with the OATP1B1 func-
tional variant, however, at weaker P values (P 5 0.0009).
Notably, previous GWAS showed signiﬁcant associations of
OATP1B1 polymorphisms with bilirubin elevation,18 although
not all reached genome-wide signiﬁcance.19 In addition, other
SNPs in OATP1B1 (r2 < 0.8 based on the 1000 Genome Project
European reference panel) were also associated with these 20
metabolites.
Cyclosporine, an OATP1B1 inhibitor, increased the plasma
levels of 12 metabolites, which were associated with
OATP1B1 Val174Ala in the GWAS
Plasma samples from 20 healthy volunteers obtained with and
without CSA administration were evaluated for metabolite levels
using the DiscoveryHD4 platform (Metabolon). The same
technology, but with less coverage, was used in the study of Shin
et al.11 Among the 20 healthy subjects who self-reported their
race as white, there were 10 volunteers who were homozygous for
the reference allele of OATP1B1-Val174Ala, 7 volunteers who
were heterozygous, and 3 who were homozygous for the
Val174Ala variant allele. A total of 956 metabolites were identi-
ﬁed, whereas 613 were metabolites of known structure and 343
were metabolites of unknown structural identity (Supplementa-
ry Table S4). Following log transformation and imputation of
missing values (see Supplementary Information), we report a
summary of 956 metabolites and their statistical signiﬁcance P
value (paired t test) and the estimate of the false discovery rate
(q-value; Supplementary Table S4). Several metabolites were sig-
niﬁcantly higher in the CSA arm compared to the placebo arm
(P < 0.05) and they belong to primary and secondary bile acids
(sulfated and glucuronidated bile acids), eicosanoids, dicarboxylic
acids, heme metabolites, and steroid sulfate and steroid glucuro-
nide conjugates. Many of these metabolites are known OATP1B1
substrates.16 In fact, these metabolites were also signiﬁcant
(P < 0.05) in the metabolomics GWAS server10 (see Table 1).
A total of 12 metabolites were signiﬁcantly associated with var-
iants in OATP1B1 when using both the GWAS data and the
CSA inhibition data (Figure 2). That is, the levels of these 12
metabolites were signiﬁcantly higher in individuals with the
OATP1B1-Val174Ala (rs4149056) variant (P < 0.05) in the
metabolomics GWAS server and in healthy volunteers following
administration of CSA/pravastatin (False Discovery Rate q-value
<0.2). Five of the 12 metabolites (X-11529, X-13429, TDA,
HDA, and X-11905) also showed a relationship with the
rs4149056 SNP in the 20 healthy volunteers following adminis-
tration of the placebo (P < 0.005; Figure 2b). Other metabolites,
including arginine, pro-hydroxy-pro, ergothioneine, and unknown
metabolites (X-11440, X-14658, and X-11438) have weaker asso-
ciations with SNPs in OATP1B1 (P > 1025) but no signiﬁcant
associations with OATP1B1-Val174Ala (P > 0.05). These metab-
olites were also not modulated upon CSA administration in the
DDI study (False Discovery Rate >0.2). Among the 12 metabo-
lites, fatty acid dicarboxylates (e.g., TDA and HDA) and 1,5-
anhydroglucitol (1,5-AG) have not been associated with
OATP1B1 previously. OATP1B1 was the top locus associated
with 9 of the 12 metabolites. The functional variant OATP1B1-
Val174Ala, or its linkage disequilibrium (LD) SNP (r2 >0.8), had
the strongest association with eight of the nine metabolites (Fig-
ure 2a and Supplementary Table S5). In addition to the 12
metabolites that were signiﬁcantly associated with SLCO1B1
genotype using both methods, other metabolites were associated
using one but not both of the methods. For example, lysolipids
(e.g., 1-arachidonoylglycerophosphoinositol [P 5 3.7 3 10231])
were signiﬁcantly associated with the SLCO1B1 locus in the
GWAS but not the CSA DDI study, perhaps because large sam-
ples would be needed in the clinical DDI study to detect differ-
ences in these metabolites. In contrast, these lysolipids may not be
substrates of OATP1B1, but their metabolic products may be sub-
strates of the transporter. Despite the fact that previous studies
have shown that total bilirubin levels (conjugated and unconjugat-
ed) were elevated in the presence of an OATP1B1 inhibitor
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Figure 2 Twelve metabolites (i to xii) significantly associated with organic anion transporter OATP1B1-Val174Ala in both a genome-wide association
study of human metabolites11 and significantly associated in healthy volunteers receiving pravastatin and cyclosporine, an OATP1B1 inhibitor. (a) Man-
hattan plots of the 12 metabolites. Manhattan plots were generated using the publicly available data, which provided the meta-analysis P values of each
single-nucleotide polymorphism (SNP; http://mips.helmholtz-muenchen.de/proj/GWAS/gwas/index.php?task5download). The large green circle repre-
sents the OATP1B1 functional variant, Val174Ala (rs4149056). Other loci, which include genes for transporters or enzymes, are labeled. OATP1B1-
Val174Ala or its linkage disequilibrium, variant (r2 >0.8) is significantly associated with eight metabolites with the strongest P values in the genome-wide
association study (GWAS; metabolites i–vii and ix). (b) The 12 metabolites significantly higher in healthy volunteers after administration of cyclosporine
(CSA) compared to placebo (P). Each dot represents the metabolite intensity in the plasma from an individual after administration of placebo (P) or cyclo-
sporine (CSA) and each line connects the metabolite intensity from the same individual following placebo or CSA administration. The color of the line rep-
resents the genotype of OATP1B1-Val174Ala, whereas blue represents homozygous reference allele, green represents heterozygous reference allele, and
red represents homozygous-reduced function variant. The P values of the paired t test between the placebo and CSA treatment group are shown in the fig-
ure. Individuals with the variant for OATP1B1-Val174Ala (after placebo administration) had significantly higher metabolites levels of X-11529, X-13429,
tetradecanedioate (TDA), hexadecanedioate (HDA), and X-11905 (P < 0.005). The mean and SD for each of the 12 metabolites in each genotype group
are shown in Supplementary Table S6. Note: X-11529, glycochenodeoxycholate glucuronide; X-13429, glycodeoxycholate sulfate or isomer; X-11905,
unknown; X-14626, unknown; 4-Andros: 4-androsten-3-beta, 17-beta-diol disulfate 20; ODA, octadecanedioate; TLS, taurolithocholate 3-sulfate; X-11440,
unknown; X-12850, glycochenodeoxycholate sulfate or isomer; 1,5-AG, 1,5-anhydroglucitol.
(rifampicin or CSA at higher dose),9,20,21 we did not observe sig-
niﬁcantly elevated levels of unconjugated bilirubin in our 20
healthy volunteers (P < 0.2). Our study may not have been sufﬁ-
ciently powered to detect the increased bilirubin levels due to its
smaller effect size (as shown in Supplementary Table S3) or sam-
ple collection times may not have been optimal for observing
changes in bilirubin levels.
Fatty acid dicarboxylates interacted with OATP1B1, but not
OATP1B3, OATP1A2, and OATP2B1
Seven of the 12 metabolites identiﬁed from the GWAS and
which also showed increased levels following CSA treatment
(Figure 1, Table 1), six were tested in the follow-up in vitro
studies: two sulfated and one glucuronidated bile acid were not
available, so we tested the two parent compounds, glycocheno-
deoxycholate and glycodeoxycholate, bearing in mind that the
results could be different for the conjugated metabolites
(Table 2). Among the ﬁve metabolites that were not followed up
in vitro, were three unknown metabolites (X-11905, X-14626,
and X-11440), and two named biochemical (octanedioic acid
and 4-androsten-3beta, 17beta-diol disulfate) that were not readi-
ly available for purchase.
We approached the in vitro studies by ﬁrst testing the metabo-
lites (at 30 lM) as competitive inhibitors of OATP1B1 and
Table 1 Twelve candidate metabolites, which are significantly associated with higher levels in subjects with minor allele C for
rs4149056 (OATP1B1-Val174Ala) with P < 0.05 and also significantly associated with higher levels in healthy volunteers (20
participants) after dosing with CSA with q <0.2
Metabolite
name Pathway
GWAS Clinical DDI study
Q valueEffecta SE P valueb Median (placebo) Median (CSA) P value
X-11529 (likely
to be glycoche-
nodeoxycholate
glucuronide)
Secondary bile
acid
metabolism
-0.30 0.0078 5.5E-315 0.55 1.54 0.0017 0.083
X-13429 (likely
to be glycodeox-
ycholate sulfate
or isomer)
Secondary bile
acid
metabolism
-0.14 0.0079 2.8E-67 0.60 1.87 5.74E-06 0.0027
TDA Fatty acid,
dicarboxylate
-0.099 0.0061 3.4E-59 0.85 1.23 0.0013 0.067
HDA Fatty acid,
dicarboxylate
-0.088 0.0058 1.7E-51 0.79 1.20 9.75E-06 0.0029
X-11905 Unknown -0.083 0.0057 1.1E-47 0.77 1.09 0.00034 0.027
X-14626 Unknown -0.053 0.0038 6.9E-44 0.38 1.53 1.53E-05 0.0029
4-Androsten-
3beta,17beta-
diol disulfate 2*
Steroid -0.049 0.0055 1.3E-18 0.92c 1.17c 0.038c 0.18c
ODA Fatty acid,
dicarboxylate
-0.029 0.005 1.0E-08 0.74c 1.10c 0.0013c 0.08c
Taurolithocho-
late 3-sulfate
Secondary bile
acid
metabolism
-0.041 0.0078 1.5E-07 0.77 1.41 0.0052 0.18
X-11440 Unknown -0.025 0.0064 0.00011 0.81c 1.18c 0.0048c 0.18c
X-12850 (likely
to be glycoche-
nodeoxycholate
sulfate)
Secondary bile
acid
metabolism
-0.019 0.0071 0.0084 0.71 1.39 0.00091 0.055
1,5-AG Glycolysis, glu-
coneogenesis,
and pyruvate
metabolism
-0.0078 0.0035 0.024 0.97 1.03 0.0051 0.18
1,5-AG, 1,5-anhydroglucitol; CSA, cyclosporine; GWAS, genome-wide association study; DDI, drug-drug interaction; HDA, hexadecanedioate; ODA, octadecanedioate; TDA,
tetradecanedioate. 2*, The sulfated species could be in different site and the exact location may not be known.
aEffect: A negative effect means that the major reference allele (T) has lower levels of the metabolites. The negative effects were observed in two independent cohorts as
described by Shin et al.11 (2014). The effect for each cohort is available in Supplementary Table S3. bThis is the meta-analysis P value. The meta-analysis was performed
using two independent cohorts, as described by Shin et al.11 (2014). The P value for each cohort is available in Supplementary Table S2. cThe reported metabolite levels,
P values, and q values after removing individuals who are homozygous for reduced function variant of OATP1B1-Val174Ala.
Note: Figure 2a shows the Manhattan plot for each of the metabolites above and Figure 2b shows the boxplot for each of the metabolites in healthy volunteers after admin-
istration of placebo or CSA.
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other OATs (Table 2). Any metabolite that inhibited >30%
was deemed an inhibitor of that transporter and was tested as a
potential substrate. This method is accurate for identifying true
inhibitors and substrates, although low potency inhibitors that
may also be substrates of the various transporters would be
missed. Among the six metabolites that were tested as inhibitors
of OATP1B1 and other organic anion-transporting polypepti-
des (OATPs), OATP1B3, OATP1A2, and OATP2B1 in trans-
fected cell lines (Table 1, Figure 1), OATP1B1 transporter
activity was inhibited >70% at 30 lM by ﬁve of the metabo-
lites (Table 2). In addition, we showed that TDA and HDA
inhibited OATP1B1 potently (IC50 1.6–4 lM; Figure 3a and
3b). Interestingly, substrate uptake by other OATPs,
OATP1B3, OATP1A2, and OATP2B1 was not inhibited by
TDA and HDA (Table 2). However, the other three metabo-
lites (glycochenodeoxycholate, glycodeoxycholate, and tauroli-
thocholate-3-sulfate) inhibited OATP1B3 and OATP2B1
>30% at 30 lM (Table 2). CSA inhibited several transporters,
including OATP1B1, OATP1B3, Na1-taurocholate co-trans-
porting polypeptide (NTCP), ABCC2, ABCB11, and ABCG2
(Table 2).
Because TDA, HDA, and 1,5-AG represent novel classes of
metabolites not known previously to interact with OATP1B1,
we tested them as substrates of the OATP1B1 in transfected
cells. TDA and HDA showed signiﬁcantly higher uptake in
HEK293 cells overexpressing OATP1B1 compared with cells
transfected with empty vector (EV; Figure 3c). Uptake of
TDA (180 nM) and HDA (12 nM) was signiﬁcantly inhibited
by CSA (10 lM; Figure 3c). In addition, cells overexpressing
OATP1B1-Val174Ala had intermediate uptake of TDA and
HDA compared with cells containing wild type OATP1B1 or
EV (Figure 3d and 3e). The 1,5-AG was not transported by
OATP1B1 (Supplementary Figure S1) and also did not inhibit
OATP1B1 at 30 lM (Table 2). Because SNPs within the
OATP1B1 locus are in linkage disequilibrium with SNPs within
or near to the genes encoding OATP1A2 and OATP1B3, and
that they share overlapping substrates, thus, we evaluated the
uptake of TDA and HDA in cells overexpressing these trans-
porters and OATP2B1. We did not observe signiﬁcant uptake
of TDA and HDA in OATP1A2, OATP1B3, and OATP2B1
transfected cells (Supplementary Figure S2).
Fatty acid dicarboxylates interacted with organic anion
transporters, OAT1 and OAT3
Primary and secondary bile acids, sulfated and glucuronidated
bile acids, steroids, and conjugates of these metabolites are sub-
strates of many transporters, including organic anion transport-
ers (OAT1, OAT2, and OAT3), NTCP, ABCC2, ABCG2,
and ABCB11.22,23 Nothing has been reported for the dicarbox-
ylic acids TDA and HDA, or 1,5-AG. Accordingly, we ﬁrst
screened the six metabolites as inhibitors of these seven trans-
porters (Table 2). TDA and HDA inhibited OAT3 (>70%)
and OAT1 (>30%) but not the other transporters. The other
metabolites had different inhibition characteristics, with 1,5-
AG not acting as an inhibitor (Table 2).Ta
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Figure 3 Inhibition (a and b) and uptake (c) studies of tetradecanedioate acid (TDA) and hexadecanedioate acid (HDA) in HEK293 cells stably expressing
organic anion transporter OATP1B1. Uptake of 3H-TDA (d) or 3H-HDA (e) with or without cyclosporine (CSA; 10 lM) in HEK293 cells stably expressing
OATP1B1 reference or OATP1B1-Val174Ala. (a and b) Representative curves of the effects of TDA and HDA on the uptake of 3H-estradiol-17b-glucuronide
(trace amount) in stably transfected HEK293 cell lines overexpressing OATP1B1. Concentrations of TDA and HDA ranged from 0.1 lM to 100 lM. (c)
HEK293 Flp-In cells, stably transfected with a plasmid containing empty vector (EV) or cDNA of OATP1B1 were incubated with a trace amount of 3H-TDA or
3H-HDA with or without 10 lM CSA. Cells were incubated with the HBSS buffer containing the substrate with or without the inhibitor for 4 min. (d and e)
Cells were incubated with the HBSS buffer containing the substrate with or without the inhibitor, CSA, for 4 minutes. A trace amount of 3H-TDA (specific
activity: 1.1 Ci/mmol) or 3H-HDA (specific activity: 89.8 Ci/mmol) was used (1:5,000 dilution). Final concentrations of 3H-TDA and 3H-HDA that were used
in the uptake studies were 180 nM and 12 nM, respectively. Fold changes are normalized to EV control uptake (without inhibitor). Results shown are the
mean6 SD for a representative experiment, performed in triplicate. The experiments were repeated in three independent experiments with similar trends
and results. ***P  0.0001; **P  0.001 (between EV and OATP1B1); ###P  0.0001; ##P  0.001 (between OATP1B1 without inhibitor and with inhib-
itor); %%P  0.01 (between OATP1B1 reference (Val174) and OATP1B1 Ala174).
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TDA and HDA were then tested as substrates of OAT1 and
OAT3 by quantifying uptake in transfected cells. Both TDA and
HDA were signiﬁcantly taken up in OAT1 and OAT3 trans-
fected cell and this was inhibited by probenecid (Figure 4a and
4b). Notably, SNPs in OAT1 and OAT3 did show weak associa-
tions with the fatty acid dicarboxylates (P values ranged from
0.007 to 0.02; Supplementary Table S5).
DISCUSSION
The importance of DDIs mediated by transporters has been well
recognized and, as a result, regulatory agencies from the United
States, Europe, and Japan have issued guidelines to drug develop-
ers that rely primarily on in vitro transporter assays to inform
decisions to conduct clinical DDI studies. Transporter assays are
mechanistic and provide considerable insight into drug transport-
er interactions. However, in vitro drug transporter interactions
may not be clinically relevant if the interaction of the compound
with the transporter is not sufﬁciently potent.6,24,25 Therefore,
other tools are needed to complement these assays to more reli-
ably predict potential clinical DDIs.
Although previous studies have used various methods in isola-
tion, such as clinical DDI studies in humans8,26 and studies in
animals (e.g., monkeys and knockout mice21,27,28) to discover bio-
markers, in this study, we used a multitiered approach combining
human genetic and metabolomic studies with in vitro methods to
discover endogenous metabolites that could serve as biomarkers
of the widely studied hepatic organic anion transporter,
OATP1B1. The beauty of such biomarkers is that they can be
used from as early as ﬁrst-in-human studies to suggest potential
in vivo DDIs before conducting costly DDI studies. As the
metabolites are measured from in vivo serum, plasma, or urine
samples, they may be more accurate in predicting DDIs than in
vitro studies of drug-transporter interactions. Ideally, an endoge-
nous biomarker for a drug transporter should be stable in the col-
lected matrix, selective for the transporter of interest,
quantitatively associated with clinical DDIs involving the trans-
porter, and not be affected by normal or disease conditions.
Measurement of the biomarker should be quantitative, accurate,
selective, sensitive, and reproducible. Our major ﬁndings were
that: (a) many metabolites were signiﬁcantly associated with
genetic variants in various SLC transporters; (b) 12 metabolites
were signiﬁcantly associated with SLCO1B1 (OATP1B1) in
both the GWAS and the CSA DDI study; (c) among six metabo-
lites tested in vitro, we identiﬁed two novel substrates of
OATP1B1; and (d) the six metabolites also interacted with other
xenobiotic enzymes and transporters.
Many metabolites were associated with genetic
variants in various SLC transporters
Data collected from the metabolomics GWAS server revealed
that many serum metabolites were strongly associated with SLC
transporter variants at genome-wide signiﬁcance (P < 5 3
1028). Some of these metabolites were documented substrates of
the transporters and replicated in other genome-wide association
studies of human metabolites (Supplementary Table S2).
Importantly, several potential new substrates were identiﬁed,
such as histidine, which was associated with the uric acid trans-
porter, SLC2A9. Further studies are clearly needed to determine
whether these metabolites are substrates of the transporters. In
addition, future studies are needed to validate if these metabolites
(Supplementary Table S1, Supplementary Table S2) can be
candidate probes for use clinically to identify drugs likely to cause
a potential transporter-mediated DDI. This would be of particu-
lar importance for transporters playing a role in the pharmacoki-
netics of many prescription drugs (e.g., OATP1B1, OAT1,
organic cation transporter 2, and multidrug and toxin extrusion
protein 1). Such biomarkers could also be useful to investigate
variation in pharmacokinetics due to genetic variants in drug
transporters.
Twelve metabolites were significantly associated
with SLCO1B1 (OATP1B1) in both the GWAS
and the CSA DDI study
OATP1B1, a highly expressed transporter in the human liver, is
known to transport a variety of endogenous metabolites, includ-
ing bile acids, steroids, bilirubin, eicosanoids, and thyroid hor-
mones (see reviews16,29). In this study, several of the known
endogenous metabolites of OATP1B1 were found to signiﬁcantly
associate with the reduced function variant of OATP1B1
(rs4149056; see Supplementary Table S3). Notably, the most
signiﬁcant association among all SLC transporters was the
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Figure 4 Uptake of 3H-tetradecanedioate acid (TDA) or 3H-
hexadecanedioate acid (HDA) in HEK293 cells stably expressing (a) organ-
ic anion transporter OAT1 and (b) OAT3. Inhibitor (Inh.) used for each trans-
porter was probenecid (100 lM for OAT1 and OAT3). Cells were incubated
with the HBSS buffer containing the tritiated substrate with or without the
inhibitor for 2 minutes. Trace amounts of 3H-TDA (specific activity: 1.1 Ci/
mmol) or 3H-HDA (specific activity: 89.8 Ci/mmol) were used (1:5,000
dilution). Final concentrations of 3H-TDA and 3H-HDA that were used in the
uptake studies were 180 nM and 12 nM, respectively. Fold changes are
normalized to empty vector (EV) control uptake (without inhibitor). Results
shown are the mean 6 SD for a representative experiment, performed in
triplicate. The experiments were repeated in three independent experi-
ments with similar significance and trend. ***P  0.0001 (between EV
and OAT1 or OAT3); ###P  0.0001; ##P  0.001 (between OAT1 or OAT3
without inhibitor and with inhibitor).
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association of X-11529 (glycochenodeoxycholate glucuronide)
levels with OATP1B1-Val174Ala (P 5 5.5 3 102315). In fact,
conjugates of bile acids represented 4 of the 12 metabolites signif-
icantly associated with OATP1B1 genetic variants. These conju-
gates also increased following administration of CSA. Consistent
with our results, a previous study has shown that genetic variants
in SLCO1B1 associated with plasma levels of glycochenodeoxy-
cholate30 as well as bilirubin glucuronide conjugates.19 However,
in the GWAS, there were signiﬁcant associations of genetic var-
iants in genes encoding other transporters (OATP1B3,
OATP1A2, MRP2, and BSEP) in addition to OATP1B1 with
conjugated bile acids (Supplementary Table S5) consistent with
multiple interactions between hepatic and intestinal transporters
and sulfate and glucuronide conjugates of bile acids.31 Because
CSA is a nonspeciﬁc OATP1B1 inhibitor with potent inhibitory
effects on transporters, such as OATP1B3, MRP2, NTCP, and
BSEP32 (Table 2), observed effects in the clinical study could be
a result of inhibition of other transporters as well. Even with this
complexity, use of these methods helped to identify potential
selective metabolites as substrates of OATP and OAT. It is worth
mentioning that the metabolomic platform that was used in our
study did not detect some metabolites that have previously been
reported as potential OATP1B1 biomarkers (e.g., coproporphyr-
ins I and III28,33). This may be due to differences in the method-
ologies used for metabolite quantiﬁcation.
Fatty acid dicarboxylates are novel substrates of OATP1B1
Among the six metabolites that were selected for in vitro studies
as inhibitors, the bile acids inhibited other OATPs and other bile
acid transporters, BSEP, NTCP, and MRP2 (Table 2). Although
not evaluated in this study, the conjugated bile acids and steroids
are likely to interact with OATP1B1 and other transporters (e.g.,
OATP1B3, OAT3, NTCP, ABCC2, ABCG2, or ABCB11) due
to evidence in the literature indicating that glucuronide and sul-
fated conjugates interact with these transporters.34,35 To our
knowledge, this study for the ﬁrst time demonstrates that fatty
acid dicarboxylates, such as TDA and HDA, respectively, are sub-
strates of OATP1B1 (Figure 3, Table 1). The results suggest
that these may be useful biomarkers of OATP1B1. Interestingly,
we noted that TDA (Supplementary Figure S3) as well as HDA
and 8 of the 10 other metabolites signiﬁcantly correlated with
pravastatin area under the curve (Supplementary Table S6) in
16 individuals with genotype TT and TC genotypes for
rs4149056 (OATP1B1-Val174Ala). TDA and HDA had a small
dynamic range whereas other metabolites (e.g., X-11529), had
larger dynamic ranges; however, TDA, HDA, as well as X-11529
correlated with pravastatin area under the curve. These data sug-
gest that the metabolites may potentially serve as quantitative
biomarkers of OATP1B1 activity, although further work is clear-
ly needed.
The metabolites were found to also associate with other
xenobiotic enzymes and transporters
Many drugs are known to interact with several metabolizing
enzymes and transporters.36 Similarly, in these studies, we noticed
that several of the metabolites that were associated at genome-
wide level signiﬁcance with SLCO1B1 were signiﬁcantly associat-
ed with metabolizing enzymes. These enzymes included
CYP4A11, which was associated with TDA and HDA levels,
and SULT2A1, which was associated with X-13429, X-12850,
and X-11440 levels (Figure 2a). This reﬂects the complexity of
endogenous metabolites disposition and metabolism, and shows
the difﬁculty in identifying biomarkers for a single enzyme or
transporter.
In order to eliminate the possibility that TDA and HDA levels
were elevated upon CSA administration in the clinical DDI
study, we evaluated whether CSA inhibit CYP4A11. In our
study, we showed that CSA did not inhibit CYP4A11 (Supple-
mentary Figure S4). However, the CYP4A11 assay shown in
Supplementary Figure S4 may suggest that fatty acid dicarboxyl-
ic acids are substrates or products of CYP4A11. This is consistent
with the information from literature that CYP4A11 has been
implicated in the production of dicarboxylic acid.37
Notably, metabolites may interact with multiple transporters.
In our study, we showed that TDA and HDA, which are sub-
strates of OATP1B1, are also substrates of the renal organic
anion transporters, OAT1 and OAT3. Although the results sug-
gest that these two fatty acid metabolites may be potential bio-
markers of these transporters, there is currently no information
about the afﬁnity of the metabolites for OATP1B1, OAT1, and
OAT3. To our knowledge, there is no published information
about the plasma concentrations of these metabolites, which
together with kinetic information is needed to validate the in
vivo relevance of OATs as determinants of the disposition of
these metabolites. Relative blood or urine concentrations of
DCA or conjugates, and factors that modulate them (e.g., disease,
nutritional status, drug intake) are not well deﬁned, with the
exception that DCA levels are elevated in patients with Reye syn-
drome.38 Use of TDA or HDA as endogenous biomarkers of
OATP1B1 alone or in combination with the OAT1 and OAT3
is intriguing and calls for further evaluation.
Future directions
Overall, from our multitiered approach, we identiﬁed endoge-
nous metabolites that interact with OATP1B1, including previ-
ously unknown substrates of the transporter. These biomarkers
may potentially be used as probes to determine whether new
drugs under development are likely perpetrators of OATP1B1-
mediated DDIs. The use of sensitive and speciﬁc endogenous bio-
markers may help drug developers avoid unnecessary clinical
DDI studies predicted from current in vitro methods.1 However,
additional clinical studies are needed to validate these metabolites
(conjugated bile acids, TDA, HDA, and conjugated steroids) and
the speciﬁcity of the biomarkers needs to be ascertained. In par-
ticular, are the biomarkers speciﬁc for OATP1B1 or do they also
serve as biomarkers for other OATs, such as OAT1 and OAT3.
Other factors, such as disease, diet, and ethnicity, which may
affect the levels of these biomarkers, should be characterized.
Finally, the sensitivity of the biomarkers (e.g., the magnitude of
change in the biomarker levels that can be detected in the pres-
ence of strong, moderate, or weak inhibitors) and their quantita-
tive relationship with changes in the levels of known OATP1B1
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model substrates (e.g., pravastatin, rosuvastatin) need to be
established.
MATERIALS AND METHODS
Genome-wide approach to identify endogenous metabolites
for SLC transporters
Several genome-wide studies have been published to identify the genetic
factors that associate with human metabolites levels.11,12,39–42 In general,
samples from these studies were collected from fasting healthy volunteers
and the metabolites were measured using different approaches. Shin
et al.11 have published a meta-analysis, which includes 7,824 adult indi-
viduals from two European populations and the associations of their
genetic variants with over 400 metabolites in blood samples. The
complete datasets are available from this link, http://mips.helmholtz-
muenchen.de/proj/GWAS/gwas/gwas_server/shin_et_al.metal.out.tar.gz.
These datasets were used as our primary discovery of endogenous metab-
olites for SLC transporters. The SNPs for all 52 family members of the
SLC transporters (total number 5 390), including 25,000 bp up and
downstream of the transcription start and stop sites and the levels for all
529 metabolites were extracted from the datasets. Metabolites and SLC
transporters with associations (P values < 1025) were extracted for
exploration and hypothesis generation.
Clinical samples for cyclosporine/pravastatin
coadministration in healthy subjects
For the clinical metabolomic study, we used plasma obtained from a
DDI study of CSA and pravastatin.43 In particular, plasma samples in 20
healthy volunteers collected 30 minutes after the second dose of CSA
(100 mg) or placebo were used for metabolite measurements. Volunteers
were genotyped for rs4149056 (Val174Ala), and included 10 who were
homozygous for the reference allele, 7 who were heterozygous, and 3
who were homozygous for the variant allele. For the correlative analysis,
we included nine and seven homozygous for the reference allele and het-
erozygous for the variant allele of rs4149056 respectively, as one subject
(who is homozygous for the reference allele) did not achieve measureable
pravastatin levels and, therefore, was omitted from the analysis. Further
information is available in Supplementary Information.
Quantification of metabolites in the clinical samples for
cyclosporine/pravastatin coadministration
Metabolites were measured in the plasma samples using the Metabolon
platform (The DiscoveryHD4 Platform), which represents a comprehen-
sive and unbiased way of identifying and quantifying metabolites. Plasma
metabolite levels in the same individuals in both cyclosporine and place-
bo were determined using the platform. Extracted plasma samples were
processed via three ultra-high-performance liquid chromatography/
tandem accurate mass spectrometry methods and an additional gas
chromatography/mass spectrometry method. Further information is
available in the Supplementary Information.
Chemicals and reagents
TDA, HDA, taurolitocholate-3-sulfate, glycochenodeoxycholate, glyco-
deoxycholate, and 1,5-AG were purchased from Sigma-Aldrich (St.
Louis, MO). [3H]-TDA was custom synthesized by Moravek Biochemi-
cals (Brea, CA). The following radiolabeled compounds were used as
model substrates for speciﬁc transporters: [3H]-esterone sulfate (Perkin
Elmer); [3H]-para-aminohippurate (American Radiolabeled Chemicals);
[3H]- guanosine 30,50-cyclic phosphate (Moravek); [3H]-cholecystokinin
octapeptide (Perkin Elmer); [3H]-taurocholic acid (Perkin Elmer); and
[3H]-estradiol-17b-D-glucuronide (Perkin Elmer). In addition, [3H]-
HDA and [3H]-1,5-AG were customized synthesized by Sanoﬁ-Aventis
(Frankfurt, Germany) see Supplementary Information.
Cell culture and in vitro transport and inhibition studies
Cells stably expressing EV, OATP1B1,44 OATP1B3,45 OAT1,46
OAT2,47 and OAT348 were cultured in the following conditions. Stably
transfected HEK-293 Flp-In cells were maintained in Dulbecco’s Modi-
ﬁed eagle medium H-21 medium supplemented with 10% fetal bovine
serum, 100 units/mL penicillin, 100 units/mL streptomycin, and
150 lg/mL hygromycin B. In some transporter studies (OATP1A2,
OATP1B1, and NTCP), HEK293T/17 (ATCC) were used for tran-
sient transfection and were cultured in the above medium but without
the hygromycin B (selection antibiotic). See Supplementary Informa-
tion for more information about the radiolabeled compounds used as
substrates for speciﬁc transporters in the inhibition studies.
Statistical analysis
The P values were determined using paired nonparametric t tests to ana-
lyze the differences in metabolite levels in plasma from placebo-treated
vs. CSA-treated healthy volunteers. An estimated false discovery rate (q
value) is calculated to take into account the multiple comparisons that
normally occur in metabolomic-based studies. False discovery rate adjust-
ment is an acceptable and alternative multiple test adjustment and par-
ticularly relevant for exploratory and data-driven testing. For exploratory
analysis of our clinical DDI study with CSA, q value <0.2 was consid-
ered signiﬁcant. Unless speciﬁed, data are expressed as mean 6 SD. For
in vitro transporter studies, statistical analyses were performed by
unpaired t tests to determine signiﬁcant differences between: (i) cells
transfected with EV or transfected with vector containing transporter
cDNA; and (ii) cells treated with no inhibitor or with inhibitor of spe-
ciﬁc transporter. The data were analyzed using GraphPad Prism 6.0 (La
Jolla, CA). A P value < 0.05 was considered statistically signiﬁcant.
Additional Supporting Information may be found in the online version of
this article.
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